Hiroshi Deguchi

US Patent:

6756208, Jun 29, 2004

Filed:

Feb 28, 2002

Appl. No.:

10/086943

Inventors:

John H. Griffin - Del Mar CA 92014
Hiroshi Deguchi - Del Mar CA 92130
Jose Fernandez - La Jolla CA 92037

International Classification:

C12Q 156

US Classification:

435 13, 536 179, 600481

Abstract:

The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.

US Patent:

20040132688, Jul 8, 2004

Filed:

Dec 17, 2003

Appl. No.:

10/739962

Inventors:

John Griffin - Del Mar CA, US
Hiroshi Deguchi - Del Mar CA, US
Jose Fernandez - La Jollal CA, US

International Classification:

A61K031/739

US Classification:

514/054000

Abstract:

The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.

US Patent:

20060263796, Nov 23, 2006

Filed:

Feb 3, 2006

Appl. No.:

11/347632

Inventors:

John Griffin - Del Mar CA, US
Hiroshi Deguchi - San Diego CA, US
Darlene Elias - San Diego CA, US
Natalie Pecheniuk - San Diego CA, US

International Classification:

C12Q 1/68
G01N 33/92

US Classification:

435006000, 436071000

Abstract:

The present invention provides methods of determining a human subject's risk for venous thrombosis based on the finding that venous thrombosis patients have significantly lower levels of large HDL particles, HDL-cholesterol and apolipoprotein Al and higher levels of small LDL particles, LDL-cholesterol and apolipoprotein B. Genotyping showed that venous thrombosis patients differed significantly from controls in CETP genotype and that the CETP genotypes found in subjects with VTE are linked to elevated CETP mass and activity. Methods for determining the level of lipids or lipoproteins in plasma or serum samples to determine risk for venous thrombosis are provided. Methods for reducing the risk of venous thrombosis are also provided.

US Patent:

20080138813, Jun 12, 2008

Filed:

Feb 3, 2006

Appl. No.:

11/815408

Inventors:

John H. Griffin - Del Mar CA, US
Hiroshi Deguchi - San Diego CA, US
Darlene J. Elias - San Diego CA, US
Natalie Pecheniuk - San Diego CA, US

International Classification:

G01N 33/92
C12Q 1/68
G01N 33/68

US Classification:

435 6, 436 71, 436 94, 435 29

Abstract:

The present invention provides methods of determining a human subject's risk for venous thrombosis based on the finding that venous thrombosis patients have significantly lower levels of large HDL particles, HDL-cholesterol and apolipoprotein AI and higher levels of small LDL particles, LDL-cholesterol and apolipoprotein B. Genotyping showed that venous thrombosis patients differed significantly from controls in CETP genotype and that the CETP genotypes found in subjects with VTE are linked to elevated CETP mass and activity. Methods for determining the level of lipids or lipoproteins in plasma or serum samples to determine risk for venous thrombosis are provided. Methods for reducing the risk of venous thrombosis are also provided.

Address:

12514 Caminito Mira Del Mar, San Diego, CA 92130

VIN:

JA4MS41X77Z020373

Make:

MITSUBISHI

Model:

OUTLANDER XLS 2WD

Year:

2007